PURPOSE: Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle progression. CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug. EXPERIMENTAL DESIGN: CCI-779 was administered weekly at a dose of 250 mg intravenously for patients on enzyme-inducing anti-epileptic drugs (EIAEDs). Patients not on EIAEDs were initially treated at 250 mg; however, the dose was reduced to 170 mg because of intolerable side effects. Treatment was continued until unacceptable toxicity, tumor progression, or patient withdrawal. The primary endpoint was 6-month progression-free survival. RESULTS: Forty-three patients were enrolled; 29 were not on EIAEDs. The expected toxicity profile of increased lipids, lymphopenia, and stomatitis was seen. There were no grade IV hematological toxicities and no toxic deaths. One patient was progression free at 6 months. Of the patients assessable for response, there were 2 partial responses and 20 with stabilization of disease. The median time to progression was 9 weeks. CONCLUSIONS: CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent GBM. Despite initial disease stabilization in approximately 50% of patients, the durability of response was short. Because of the low toxicity profile, CCI-779 may merit exploration in combination with other modalities.
PURPOSE: Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle progression. CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug. EXPERIMENTAL DESIGN:CCI-779 was administered weekly at a dose of 250 mg intravenously for patients on enzyme-inducing anti-epileptic drugs (EIAEDs). Patients not on EIAEDs were initially treated at 250 mg; however, the dose was reduced to 170 mg because of intolerable side effects. Treatment was continued until unacceptable toxicity, tumor progression, or patient withdrawal. The primary endpoint was 6-month progression-free survival. RESULTS: Forty-three patients were enrolled; 29 were not on EIAEDs. The expected toxicity profile of increased lipids, lymphopenia, and stomatitis was seen. There were no grade IV hematological toxicities and no toxic deaths. One patient was progression free at 6 months. Of the patients assessable for response, there were 2 partial responses and 20 with stabilization of disease. The median time to progression was 9 weeks. CONCLUSIONS:CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent GBM. Despite initial disease stabilization in approximately 50% of patients, the durability of response was short. Because of the low toxicity profile, CCI-779 may merit exploration in combination with other modalities.
Authors: Viktor Grünwald; Linda DeGraffenried; Douglas Russel; William E Friedrichs; Ratna B Ray; Manuel Hidalgo Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: B Geoerger; K Kerr; C B Tang; K M Fung; B Powell; L N Sutton; P C Phillips; A J Janss Journal: Cancer Res Date: 2001-02-15 Impact factor: 12.701
Authors: Joseph F Gera; Ingo K Mellinghoff; Yijiang Shi; Matthew B Rettig; Chris Tran; Jung-hsin Hsu; Charles L Sawyers; Alan K Lichtenstein Journal: J Biol Chem Date: 2003-10-23 Impact factor: 5.157
Authors: H Hosoi; M B Dilling; L N Liu; M K Danks; T Shikata; A Sekulic; R T Abraham; J C Lawrence; P J Houghton Journal: Mol Pharmacol Date: 1998-11 Impact factor: 4.436
Authors: Frederick F Lang; Mark R Gilbert; Vinay K Puduvalli; Jeffrey Weinberg; Victor A Levin; W K Alfred Yung; Raymond Sawaya; Gregory N Fuller; Charles A Conrad Journal: Neuro Oncol Date: 2002-10 Impact factor: 12.300
Authors: R Schober; T Bilzer; A Waha; G Reifenberger; W Wechsler; A von Deimling; O D Wiestler; M Westphal; J T Kemshead; F Vega Journal: Clin Neuropathol Date: 1995 May-Jun Impact factor: 1.368
Authors: Jann N Sarkaria; Eva Galanis; Wenting Wu; Allan B Dietz; Timothy J Kaufmann; Michael P Gustafson; Paul D Brown; Joon H Uhm; Ravi D Rao; Laurence Doyle; Caterina Giannini; Kurt A Jaeckle; Jan C Buckner Journal: Clin Cancer Res Date: 2010-10-04 Impact factor: 12.531
Authors: Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer Journal: Invest New Drugs Date: 2011-12-09 Impact factor: 3.850
Authors: David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine B Peters; Sith Sathornsumetee; Stevie Threatt; John H Sampson; James E Herndon; April Coan; Frances McSherry; Jeremy N Rich; Roger E McLendon; Steven Zhang; Henry S Friedman Journal: J Neurooncol Date: 2012-03-10 Impact factor: 4.130
Authors: Eudocia Q Lee; John Kuhn; Kathleen R Lamborn; Lauren Abrey; Lisa M DeAngelis; Frank Lieberman; H Ian Robins; Susan M Chang; W K Alfred Yung; Jan Drappatz; Minesh P Mehta; Victor A Levin; Kenneth Aldape; Janet E Dancey; John J Wright; Michael D Prados; Timothy F Cloughesy; Mark R Gilbert; Patrick Y Wen Journal: Neuro Oncol Date: 2012-10-24 Impact factor: 12.300
Authors: Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701